Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery
Official title: Construction of a Post-operative Multimodal Survival Prediction Model for Patients With Colorectal Liver Metastases: A Study Based on the Fusion of a Multicenter Cohort and High-dimensional Radiomics
Run by Anhui Provincial Hospital · NCT07830576 · Data updated 2026-11-12
Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 205 (estimated) |
| Sponsor | Anhui Provincial Hospital Government |
| Locations | 1 site (Hefei, Anhui) |
| Status | Recruiting |
| Started | February 1, 2017 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT07830576 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with confirmed colorectal cancer and liver metastases who had surgical resection and have high-quality preoperative liver MRI available for radiomics.
✕Probably not a fit
Patients without available preoperative MRI data or with non-resected disease may not benefit from this prognostic model.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects data from a multicenter cohort of adults who had surgical resection for colorectal liver metastases. It extracts 3D radiomics features from preoperative MRI to capture tumor micro-heterogeneity, then combines these with clinical parameters such as liver function and tumor biomarkers. A machine learning approach reduces dimensionality and builds a prognostic nomogram to predict post-operative survival, with internal and external validation to assess generalizability. The goal is a non-invasive, data-driven means to support personalized follow-up and adjuvant treatment decisions.
Why it matters
Potential benefit: If successful, clinicians could use the nomogram to tailor post-operative monitoring and therapies to individual risk profiles.
How similar studies have gone: Prior work in radiomics and nomogram-based prognosis has shown promise, but external validation in CRLM is ongoing.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Age \>= 18 years old. Confirmed diagnosis of colorectal cancer with liver metastases (CRLM). Underwent surgical resection for colorectal liver metastases. Preoperative liver magnetic resonance imaging (MRI) was performed with high-quality images available for 3D radiomics feature extraction. Complete baseline clinical, laboratory, and post-operative follow-up survival data. Exclusion Criteria: Patients who received local ablation only (such as radiofrequency ablation) without surgical resection. Preoperative MRI images with severe artifacts or poor quality that prevent high-throughput radiomics analysis. Concurrent history of other primary malignant neoplasms. Missing key clinical variables or lost to follow-up immediately after surgical intervention.
Where it's running
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China Recruiting
Study contacts
- Principal investigator: Jizhou Wang, MD, PhD — The First Affiliated Hospital of University of Science and Technology of China
- Study coordinator: can zhang
- Email: 15755077865@163.com
- Phone: +8615755077865
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Biomarkers in Colorectal Cancer: A Longitudinal Study Using Biobanks and Blood Samples
This study tests whether clinical and molecular biomarkers from tumor tissue and blood can predict treatment response, recurrence, and survival in adults with colorectal cancer undergoing surgery.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
ctDNA blood test to spot buried cancer after surgery or treatment in colorectal cancer
A blood test that looks for specific KRAS mutations in circulating tumor DNA to see if colorectal cancer has left residual disease or is likely to relapse.
-
Methylscape test in body fluids for multi-cancer detection in Colombia
A simple blood, urine, or saliva test called Methylscape is being tested to see if it can detect multiple cancers and identify where the signal is coming from, using people with cancer and healthy volunteers in Colombia.
-
AI-powered stool image analysis to see if it matches FIT results in colorectal cancer screening
We’re testing whether AI-derived features from stool images can align with FIT results in adults being screened or evaluated for colorectal neoplasia.
-
Predicting liver failure after major liver surgery using CT measurements and vascular shape changes
Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.